|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 293.20 SEK | -3.30% |
|
-3.68% | -7.62% |
| 06-12 | Swedish Orphan Biovitrum AB - Special Call | |
| 06-12 | Sobi presents new clinical data on hematological diseases at congress | FW |
| Capitalization | 101B 10.66B 9.21B 8.67B 7.84B 14.51B 912B 16.34B 39.32B 419B 39.97B 39.13B 1,531B | P/E ratio 2025 * |
21.7x | P/E ratio 2026 * | 16.3x |
|---|---|---|---|---|---|
| Enterprise value | 109B 11.51B 9.94B 9.36B 8.47B 15.67B 986B 17.65B 42.46B 453B 43.18B 42.27B 1,654B | EV / Sales 2025 * |
3.87x | EV / Sales 2026 * | 3.21x |
| Free-Float |
51.66% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Swedish Orphan Biovitrum AB
More recommendations
More press releases
| 1 day | -3.30% | ||
| 1 week | -3.68% | ||
| 1 month | -2.20% | ||
| 3 months | +3.90% | ||
| 6 months | -7.51% | ||
| Current year | -7.62% |
| 1 week | 289 |  | 309.2 |
| 1 month | 289 | | 312.6 |
| Current year | 241.8 | | 349.4 |
| 1 year | 241.8 | | 354.4 |
| 3 years | 197.9 | | 354.4 |
| 5 years | 127.1 | | 354.4 |
| 10 years | 89.5 | | 354.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Guido Oelkers
CEO | Chief Executive Officer | 60 | 22/05/2017 |
Henrik Stenqvist
DFI | Director of Finance/CFO | 58 | 20/07/2018 |
| Chief Tech/Sci/R&D Officer | 54 | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 05/05/2011 | |
Staffan Schüberg
BRD | Director/Board Member | 56 | 01/01/2020 |
| Director/Board Member | 69 | 01/01/2021 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 1.15% | 240 M€ | -3.21% | - | |
| 0.9% | 4 M€ | +20.16% | - | |
| 0.48% | 0 M€ | -.--% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -3.30% | -3.68% | +9.08% | +36.37% | 10.9B | ||
| +0.21% | -0.79% | -14.59% | -11.18% | 76.01B | ||
| -1.34% | +2.90% | +39.05% | +26.88% | 54.19B | ||
| -0.76% | +1.30% | +24.47% | +101.02% | 35.97B | ||
| -0.56% | +1.50% | -42.63% | -33.01% | 19.5B | ||
| +1.00% | +8.75% | +131.71% | +201.87% | 16.82B | ||
| +0.61% | +7.74% | +44.80% | +849.13% | 15.92B | ||
| -0.04% | -.--% | +93.36% | +148.72% | 14.02B | ||
| +0.54% | +2.94% | +15.48% | -1.68% | 13.33B | ||
| -1.29% | -14.99% | -0.57% | -28.26% | 11.87B | ||
| Average | -0.51% | +1.30% | +30.02% | +128.99% | 26.85B | |
| Weighted average by Cap. | -0.46% | +1.03% | +20.83% | +84.29% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 28.14B 2.98B 2.57B 2.42B 2.19B 4.05B 255B 4.57B 10.98B 117B 11.17B 10.93B 428B | 31.64B 3.35B 2.89B 2.72B 2.46B 4.56B 287B 5.13B 12.35B 132B 12.56B 12.3B 481B |
| Net income | 4.61B 488M 421M 397M 359M 664M 41.78B 748M 1.8B 19.19B 1.83B 1.79B 70.11B | 6.1B 646M 558M 525M 475M 879M 55.3B 990M 2.38B 25.41B 2.42B 2.37B 92.81B |
| Net Debt | 8.06B 853M 737M 694M 628M 1.16B 73.07B 1.31B 3.15B 33.57B 3.2B 3.13B 123B | 941M 99.59M 86.04M 81.01M 73.3M 136M 8.53B 153M 367M 3.92B 374M 366M 14.31B |
More financial data
* Estimated data
Employees
1,895
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/06/25 | 293.20 kr | -3.30% | 389,704 |
| 11/06/25 | 303.20 kr | +3.62% | 706,024 |
| 10/06/25 | 292.60 kr | -4.69% | 565,921 |
| 09/06/25 | 307.00 kr | -0.07% | 238,264 |
| 05/06/25 | 307.20 kr | +0.92% | 227,296 |
Delayed Quote Nasdaq Stockholm, June 12, 2025 at 07:00 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
293.20SEK
Average target price
353.09SEK
Spread / Average Target
+20.43%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SOBI Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition